Rajvi Mehta, MD
Ophthalmology · San Mateo
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 30
- 8 carriers
- Offices
- 2
Offices
2 locations · A Sydney Williams and Associates Inc · Thomas Tayeri M D Inc
Looking this up.
Hospitals listed: Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plans that list them
30 plans · 8 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Mehta’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
30 of 30 plans
| Aetna Medicare Enhanced (HMO-POS) | Aetna Medicare | Listed | Sep 8, 2026 |
| Aetna Medicare Enhanced Extra (HMO-POS) | Aetna Medicare | Listed | Sep 8, 2026 |
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$153,195
Medicare paid this office $153,195 for 308 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Established patient complete exam of visual system | 158 | $42,481 | $115 |
| Short return visit (20+ min) | 127 | $20,492 | $79 |
| Exam of visual field with extended testing | 166 | $13,219 | $62 |
| Removal of cataract with insertion of prosthetic lens | 17 | $11,744 | $452 |
| Imaging of optic nerve | 187 | $7,065 | $33 |
See all 11 services
| Established patient complete exam of visual system | 158 | $42,481 | $115 |
| Short return visit (20+ min) | 127 | $20,492 | $79 |
| Exam of visual field with extended testing | 166 | $13,219 | $62 |
| Removal of cataract with insertion of prosthetic lens | 17 | $11,744 | $452 |
| Imaging of optic nerve | 187 | $7,065 | $33 |
| New patient complete exam of visual system | 25 | $3,058 | $122 |
| New patient visit (45+ min) | 13 | $1,887 | $145 |
| Exam of the internal drainage system of eye | 57 | $1,376 | $24 |
| Measurement of corneal curvature and depth of eye | 26 | $1,300 | $41 |
| Ct scan of cornea | 16 | $541 | $32 |
| Ultrasound scan of cornea to determine thickness | 32 | $326 | $10 |
Procedures Medicare counted
| Cataract surgery | 59 | More than 66% of doctors who do this |
Who their Medicare patients are
308 Original Medicare patients in 2024. Average age 77 · Women 58% · Also on Medicaid 8% · Health risk score 0.93. At or below the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 66% · Coronary heart disease 20% · Chronic kidney disease 18% · Diabetes 17% · Cancer 17% · Atrial fibrillation 16% · Heart failure 11% · Depression 9% · COPD 6% · Stroke 6% · Dementia 4%.
The office billed $446,885, Medicare allowed $204,463 and paid $153,195; for 1,387 services of 39 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 308 | 1,387 | 77 | 0.93 | $446,885 | $153,195 |
| 2023 | 298 | 1,309 | 78 | 1.01 | $370,485 | $123,764 |
| 2022 | 187 | 390 | 78 | 0.98 | $98,035 | $33,797 |
| 2021 | 30 | 37 | 75 | 1.55 | $13,338 | $3,213 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 13 services
| Established patient complete exam of visual system | 147 | $32,068 | $106 |
| Short return visit (20+ min) | 111 | $14,792 | $74 |
| Exam of visual field with extended testing | 160 | $12,064 | $56 |
| Removal of cataract with insertion of prosthetic lens | 12 | $6,841 | $456 |
| Imaging of optic nerve | 158 | $5,643 | $30 |
| Destruction of lens tissue using laser | 15 | $5,443 | $340 |
| Return visit (30+ min) | 46 | $4,163 | $83 |
| New patient visit (45+ min) | 30 | $3,585 | $120 |
| New patient complete exam of visual system | 26 | $3,139 | $121 |
| Established patient problem focused exam of visual system | 15 | $1,699 | $81 |
| Exam of the internal drainage system of eye | 62 | $1,627 | $24 |
| Measurement of corneal curvature and depth of eye | 19 | $799 | $38 |
| Ultrasound scan of cornea to determine thickness | 46 | $440 | $9 |
2022: 11 services
| Established patient complete exam of visual system | 60 | $8,490 | $125 |
| Return visit (30+ min) | 36 | $3,753 | $101 |
| Exam of visual field with extended testing | 55 | $3,410 | $60 |
| Established patient problem focused exam of visual system | 25 | $2,224 | $89 |
| Short return visit (20+ min) | 30 | $1,933 | $62 |
| Creation of shunt to improve eye fluid flow using tissue graft | 12 | $1,665 | $139 |
| Imaging of optic nerve | 51 | $1,636 | $31 |
| Imaging of retina | 11 | $464 | $36 |
| Exam of the internal drainage system of eye | 17 | $432 | $25 |
| Photography of the retina | 12 | $417 | $35 |
| Ultrasound scan of cornea to determine thickness | 16 | $163 | $10 |
2021: 1 service
| Short return visit (20+ min) | 14 | $993 | $71 |
Medicaid work
$1,766 in 2024
Medicaid paid $1,766 for 31 billed services this clinician did in 2024, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 31 | $1,766 |
| 2024 | 31 | 1 | 14 | $1,766 |
| 2023 | 14 | 1 | 14 | $286 |
See the largest Medicaid services in earlier years
2023
| Short return visit (20+ min) | 14 | $286 |
Drugs they prescribed that Part D paid
$106,534
Pharmacies billed $106,534 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 690) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
378 generic and 312 brand-name prescriptions · $106,534 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rocklatan | 27 | $19,391 | $718 |
| Vyzulta | 29 | $14,645 | $505 |
| Xiidra | 14 | $13,394 | $957 |
| Lumigan | 21 | $11,913 | $567 |
| Rhopressa | 16 | $6,860 | $429 |
See all 18 drugs
| Rocklatan | 27 | $19,391 | $718 |
| Vyzulta | 29 | $14,645 | $505 |
| Xiidra | 14 | $13,394 | $957 |
| Lumigan | 21 | $11,913 | $567 |
| Rhopressa | 16 | $6,860 | $429 |
| Simbrinza | 26 | $6,310 | $243 |
| Brimonidine Tartrate-Timolol | 20 | $5,703 | $285 |
| Dorzolamide-Timolol | 24 | $3,302 | $138 |
| Prednisolone Acetate | 46 | $2,076 | $45 |
| Brimonidine | 80 | $1,776 | $22 |
| Brinzolamide | 16 | $1,758 | $110 |
| Latanoprost | 108 | $1,246 | $12 |
| Dorzolamide-Timolol | 50 | $1,015 | $20 |
| Timolol Maleate | 63 | $549 | $9 |
| Ofloxacin | 28 | $296 | $11 |
| Ketorolac Tromethamine | 21 | $262 | $12 |
| Dorzolamide | 11 | $131 | $12 |
| Erythromycin | 11 | $81 | $7 |
Year by year
| 2024 | 690 | 130 | 0% (0) | 45% | $106,534 |
| 2023 | 731 | 247 | 0% (0) | 42% | $94,151 |
| 2022 | 2,340 | 689 | None | 34% | $255,336 |
| 2021 | 999 | 445 | None | 37% | $92,703 |
| 2020 | 352 | 119 | 0% (0) | 40% | $236,629 |
| 2019 | 193 | 74 | 0% (0) | 34% | $12,201 |
| 2018 | 81 | 38 | 0% (0) | 22% | $4,153 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 20 drugs
| Lumigan | 29 | $14,248 | $491 |
| Vyzulta | 22 | $11,714 | $532 |
| Rocklatan | 20 | $8,413 | $421 |
| Alphagan P | 15 | $6,008 | $401 |
| Simbrinza | 21 | $5,196 | $247 |
| Combigan | 13 | $5,175 | $398 |
| Rhopressa | 12 | $4,993 | $416 |
| Methazolamide | 11 | $4,746 | $431 |
| Brinzolamide | 11 | $3,923 | $357 |
| Latanoprost | 168 | $3,520 | $21 |
| Dorzolamide-Timolol | 18 | $2,361 | $131 |
| Brimonidine | 87 | $2,212 | $25 |
| Prednisolone Acetate | 43 | $2,104 | $49 |
| Dorzolamide-Timolol | 72 | $2,101 | $29 |
| Timolol Maleate | 51 | $771 | $15 |
| Dorzolamide | 16 | $700 | $44 |
| Ketorolac Tromethamine | 15 | $446 | $30 |
| Ofloxacin | 28 | $320 | $11 |
| Moxifloxacin | 11 | $243 | $22 |
| Erythromycin | 14 | $180 | $13 |
2022: 25 drugs
| Rhopressa | 60 | $28,559 | $476 |
| Alphagan P | 70 | $25,873 | $370 |
| Rocklatan | 39 | $23,282 | $597 |
| Lumigan | 54 | $23,273 | $431 |
| Restasis | 18 | $23,040 | $1,280 |
| Latanoprost | 690 | $15,742 | $23 |
| Combigan | 34 | $13,442 | $395 |
| Dorzolamide-Timolol | 65 | $11,037 | $170 |
| Brinzolamide | 42 | $9,794 | $233 |
| Brimonidine | 269 | $9,248 | $34 |
| Dorzolamide-Timolol | 306 | $8,627 | $28 |
| Azopt | 17 | $7,328 | $431 |
| Travoprost | 35 | $6,991 | $200 |
| Brimonidine Tartrate-Timolol | 19 | $5,960 | $314 |
| Simbrinza | 20 | $5,847 | $292 |
| Prednisolone Acetate | 125 | $5,301 | $42 |
| Travatan Z | 14 | $5,136 | $367 |
| Zioptan | 12 | $4,193 | $349 |
| Dorzolamide | 143 | $3,726 | $26 |
| Acetazolamide | 15 | $2,813 | $188 |
| Timolol Maleate | 126 | $1,760 | $14 |
| Ketorolac Tromethamine | 25 | $992 | $40 |
| Ciprofloxacin | 13 | $181 | $14 |
| Erythromycin | 14 | $172 | $12 |
| Polymyxin B Sul-Trimethoprim | 18 | $157 | $9 |
2021: 16 drugs
| Rocklatan | 18 | $11,302 | $628 |
| Alphagan P | 21 | $7,283 | $347 |
| Combigan | 27 | $7,054 | $261 |
| Latanoprost | 261 | $6,396 | $25 |
| Lumigan | 20 | $6,031 | $302 |
| Brinzolamide | 18 | $5,718 | $318 |
| Brimonidine | 104 | $5,536 | $53 |
| Prednisolone Acetate | 113 | $4,671 | $41 |
| Travoprost | 18 | $4,539 | $252 |
| Dorzolamide-Timolol | 109 | $2,895 | $27 |
| Dorzolamide | 62 | $1,995 | $32 |
| Timolol Maleate | 52 | $1,037 | $20 |
| Ketorolac Tromethamine | 20 | $862 | $43 |
| Atropine Sulfate | 13 | $711 | $55 |
| Ofloxacin | 18 | $280 | $16 |
| Polymyxin B Sul-Trimethoprim | 24 | $189 | $8 |
2020: 7 drugs
| Prednisolone Acetate | 58 | $2,467 | $43 |
| Brimonidine | 42 | $1,493 | $36 |
| Latanoprost | 57 | $1,234 | $22 |
| Dorzolamide-Timolol | 21 | $1,013 | $48 |
| Dorzolamide | 21 | $742 | $35 |
| Timolol Maleate | 19 | $388 | $20 |
| Ofloxacin | 14 | $285 | $20 |
2019: 6 drugs
| Latanoprost | 37 | $816 | $22 |
| Prednisolone Acetate | 22 | $734 | $33 |
| Brimonidine | 12 | $684 | $57 |
| Erythromycin | 34 | $540 | $16 |
| Dorzolamide-Timolol | 12 | $433 | $36 |
| Dorzolamide | 12 | $294 | $25 |
2018: 1 drug
| Erythromycin | 12 | $133 | $11 |
Money from drug and device companies
$672 in 2025
| 2025 | 10 | 12 | None | $672 |
| 2024 | 4 | 7 | None | $480 |
| 2023 | 4 | 7 | None | $380 |
| 2022 | 2 | 2 | None | $87 |
| 2021 | 1 | 1 | None | $62 |
| 2020 | 2 | 2 | None | $45 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Alcon Vision | Hydrus Microstent | $186 | 2 payments
|
| Genentech | Susvimo | $144 | 1 payment
|
| Biotissue Holdings | None | $129 | 1 payment
|
| Dompe US | Oxervate | $53 | 2 payments
|
| Sight Sciences | Omni Surgical System | $36 | 1 payment
|
| Abbvie | Lumigan | $28 | 1 payment
|
See all 12 published payments
| Ocular Therapeutix | Meals · 2025-12-08 | Dextenza | $24 |
| Oyster Point Pharma | Meals · 2025-11-01 | Ryzumvi | $24 |
| Dompe US | Meals · 2025-10-29 | Oxervate | $26 |
| Biotissue Holdings | Meals · 2025-10-09 | None | $129 |
| Dompe US | Meals · 2025-09-19 | Oxervate | $27 |
| Genentech | Meals · 2025-07-17 | Susvimo | $144 |
| Abbvie | Meals · 2025-07-11 | Lumigan | $28 |
| Alcon Vision | Meals · 2025-06-17 | Hydrus Microstent | $159 |
| Sight Sciences | Meals · 2025-05-21 | Omni Surgical System | $36 |
| Alcon Vision | Meals · 2025-05-09 | Clareon | $27 |
| Bausch & Lomb Americas | Meals · 2025-03-31 | Xiidra | $25 |
| Thea Pharma | Meals · 2025-01-15 | Iyuzeh | $24 |
See earlier years (2024, 2023, 2022, 2021, 2020)
2024: $480
| Sight Sciences | Omni Surgical System | $179 | 3 payments
|
| RxSight | Rxsight Contact Lens | $138 | 2 payments
|
| Bausch & Lomb Americas | Vyzulta | $138 | 1 payment
|
| Tarsus Pharmaceuticals | Xdemvy | $25 | 1 payment
|
2023: $380
| Alcon Vision | Hydrus Microstent | $272 | 2 payments
|
| Sight Sciences | Omni Surgical System | $66 | 3 payments
|
| Bausch & Lomb Americas | Vyzulta | $23 | 1 payment
|
| Thea Pharma | Iyuzeh | $19 | 1 payment
|
2022: $87
| Sight Sciences | Omni(R) Surgical System (US) | $68 | 1 payment
|
| Alcon Vision | Hydrus Microstent | $18 | 1 payment
|
2021: $62
| Sight Sciences | Omni(R) Surgical System (US) | $62 | 1 payment
|
2020: $45
| Bausch & Lomb a division of Bausch Health US | Vyzulta | $23 | 1 payment
|
| Alcon Vision | Acrysof | $21 | 1 payment
|
Professional record
- NPI
- 1942732995
- Licence
- NC 2021-01557
- Trained
- Duke University School of Medicine, 2017
- Group
- A Sydney Williams and Associates Inc · Thomas Tayeri M D Inc
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 101 S San Mateo Dr Ste 306, San Mateo, CA, 94401
- NPI first listed
- 2017-03-29
- NPI last updated
- 2026-07-14
- NPI record certified
- 2026-07-14
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: Suny Stony Brook Hospital, Stony Brook, NY, 11794